Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00474942 · ClinicalTrials.gov registry record

Natural History of Apparent Mineralocorticoid Excess Syndrome

A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
130
Enrollment target

NCT00474942 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 130 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00474942 has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
130 participants
Enrollment target

Study Summary

Apparent mineralocorticoid excess (AME) is a rare inherited disease that can cause severe high blood pressure and low blood potassium in children and adults. It is caused by abnormal hormone metabolism and can be fatal. This study will focus on the genetic basis, natural history, disease progression, and survival of people with AME.

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2007-04
Est. Completion 2013-11

What the Registry Record Tells You About NCT00474942

The ClinicalTrials.gov registry entry for NCT00474942 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00474942 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00474942 about?

NCT00474942 is a clinical study titled "Natural History of Apparent Mineralocorticoid Excess Syndrome". Apparent mineralocorticoid excess (AME) is a rare inherited disease that can cause severe high blood pressure and low blood potassium in children and adults. It is caused by abnormal hormone metabolism and can be fatal. This study will focus on the genetic basis, natural history, disease progression...

What is the current status of trial NCT00474942?

This trial is currently completed. The enrollment target is 130 participants. The study started on 2007-04. Estimated completion is 2013-11.

Who is sponsoring clinical trial NCT00474942?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.